: Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone. The trial met its end point of maintenance of a hematocrit target (≤45%) without thrombotic events, progression of leukocytosis, thrombocytosis, and worsening of splenomegaly in the ropeginterferon alfa-2b group.
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera / Barbui, Tiziano; Vannucchi, Alessandro Maria; De Stefano, Valerio; Carobbio, Alessandra; Ghirardi, Arianna; Carioli, Greta; Masciulli, Arianna; Rossi, Elena; Ciceri, Fabio; Bonifacio, Massimiliano; Iurlo, Alessandra; Palandri, Francesca; Benevolo, Giulia; Pane, Fabrizio; Ricco, Alessandra; Carli, Giuseppe; Caramella, Marianna; Rapezzi, Davide; Musolino, Caterina; Siragusa, Sergio; Rumi, Elisa; Patriarca, Andrea; Cascavilla, Nicola; Mora, Barbara; Cacciola, Emma; Mannarelli, Carmela; Loscocco, Giuseppe Gaetano; Guglielmelli, Paola; Gesullo, Francesca; Betti, Silvia; Lunghi, Francesca; Scaffidi, Luigi; Bucelli, Cristina; Vianelli, Nicola; Bellini, Marta; Finazzi, Maria Chiara; Tognoni, Gianni; Rambaldi, Alessandro. - In: NEJM EVIDENCE. - ISSN 2766-5526. - 2:6(2023), pp. EVIDoa2200335-EVIDoa2200335. [10.1056/EVIDoa2200335]
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
Carobbio, Alessandra;
2023
Abstract
: Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone. The trial met its end point of maintenance of a hematocrit target (≤45%) without thrombotic events, progression of leukocytosis, thrombocytosis, and worsening of splenomegaly in the ropeginterferon alfa-2b group.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
